The Institute for Clinical and Economics Review will discuss with stakeholders at a June 30 meeting its findings on abaloparatide and teriparatide, two anabolic agents used in osteoporosis treatment.
According to a press release issued by ICER, there wasn’t enough evidence to distinguish between the two agents.
“Abaloparatide and teriparatide are important treatment options for patients for whom other therapies have not been effective, “ICER’s Chief Medical Officer Dr. David Rind said in the press release. “Our report suggests that the evidence is inadequate to distinguish among the available options, and that estimated price after rebates remains too high for both drugs to align well with the added benefit they bring to patients.”
ICER’s report also includes a summary of romosozumab trial results. Romosozumab is another agent used to treat Osteoporosis.
According to the release, ICER will discuss the report during a California Technology Assessment Forum meeting, which is slated for June 30.
During the meeting, ICER will “also engage stakeholders in addressing how best to apply the available evidence to pricing and coverage to ensure that patients can receive appropriate care.”